Mice injected with ERBB2-positive LLC1 cancer cells, upon appearance of tumours > =100 mm3 in volume were randomized and subjected to placebo, or to anti-PD1 antibody (days 0, 3, 7, 10, 14, 17 from appearance of tumour), or to combined anti-PD1 treatments (schedule as above) with either R-LM113 or SurE_oHSV viruses (0.5 × 108 PFU at days 0, 2, 4, 7) (Fig. 5a). This evidence concerns the gene ERBB2 and cancer.